MMJ BioPharma Cultivation, a subsidiary of MMJ International Holdings, is publicly challenging the United States government’s approach to marijuana regulation. The company argues that the current policy presents a stark contradiction: offering tax breaks to state-level marijuana businesses operating outside federal law, while simultaneously obstructing federally compliant medical cannabis research.
Duane Boise, President and CEO of MMJ International Holdings, expressed concern over this discrepancy. He noted the administration’s efforts to intercept drug shipments from Venezuela while simultaneously allowing illegal marijuana operators significant tax advantages through proposed changes to IRS Section 280E. He emphasized the incongruity of this approach.
Currently, state marijuana operators remain illegal under the Controlled Substances Act (CSA). However, proposed legislation aims to ease their tax burden by allowing deductions for ordinary business expenses. This could reduce their effective tax rates considerably. Meanwhile, MMJ BioPharma Cultivation, which is pursuing FDA-approved clinical trials for cannabinoid-based therapies targeting Huntington’s disease and Multiple Sclerosis, has been denied cultivation registration by the DEA for over seven years.
This delay, according to Boise, not only impedes scientific progress but also deprives patients of potentially life-changing treatments. The company holds Orphan Drug Designations for both diseases, indicating a significant unmet medical need.
The company’s argument centers on the disparity between actions taken against international drug cartels and the treatment of domestic marijuana operators. Boise questioned the DEA‘s priorities, suggesting that rewarding illegal activity while hindering legitimate research contradicts the agency’s stated mission.
MMJ BioPharma Cultivation is calling on the Trump administration and DEA Administrator Terry Cole to address this issue directly. The company urges immediate approval for its cultivation registration, enabling it to proceed with its research. Furthermore, they advocate for a clear distinction between recreational marijuana commerce and FDA-regulated cannabinoid research.
Boise concluded by stating that patients need effective medicine, not more dispensaries, urging the DEA to prioritize science and public health over political considerations. MMJ is represented by attorney Megan Sheehan and is dedicated to developing FDA-compliant cannabinoid medicines. The company’s commitment to regulatory compliance and patient care underscores its frustration with the current policy.
Related
